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Abstract
Background Activated charcoal is commonly used to
manage overdose or accidental ingestion of medicines.
This study evaluated the effect of activated charcoal on
apixaban exposure in human subjects.
Methods This was an open-label, three-treatment, three-
period, randomized, crossover study of single-dose apix-
aban (20 mg) administered alone and with activated char-
coal given at 2 or 6 h post-dose to healthy subjects. Blood
samples for assay of plasma apixaban concentration were
collected up to 72 h post-dose. Pharmacokinetic parame-
ters, including peak plasma concentration (Cmax), time to
Cmax (Tmax), area under the concentration–time curve from
time 0 to infinity (AUCINF), and terminal half-life (T),
were derived from apixaban plasma concentration–time
data. A general linear mixed-effect model analysis of Cmax
and AUCINF was performed to estimate the effect of acti-
vated charcoal on apixaban exposure.
Results A total of 18 subjects were treated and completed
the study. AUCINF for apixaban without activated charcoal
decreased by 50 and 28 %, respectively, when charcoal
was administered at 2 and 6 h post-dose. Apixaban Cmax
and Tmax were similar across treatments. The mean T for
apixaban alone (13.4 h) decreased to *5 h when activated
charcoal was administered at 2 or 6 h post-dose. Overall,
apixaban was well tolerated in this healthy population, and
most adverse events were consistent with the known profile
of activated charcoal.
Conclusion Administration of activated charcoal up to
6 h after apixaban reduced apixaban exposure and facili-
tated the elimination of apixaban. These results suggest
that activated charcoal may be useful in the management of
apixaban overdose or accidental ingestion.
1 Introduction
Apixaban is a highly selective, potent inhibitor of both free
and prothrombinase-bound factor Xa [1, 2]. Apixaban has
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been approved in multiple countries for the prevention of
stroke and systemic embolism in patients with non-valvular
atrial fibrillation [3, 4] and for thromboprophylaxis follow-
ing elective knee or hip replacement surgery [5, 6]. It is also
under development for the treatment of acute symptomatic
deep vein thrombosis [7]. Although the risk of bleeding
complications with apixaban is lower than that with warfarin
in patients with atrial fibrillation [4], the potential for
bleeding remains a concern with all anticoagulants in the
event of overdose or accidental ingestion. Agents such as
protamine, fresh frozen plasma, prothrombin complex con-
centrate, and vitamin K have been used successfully to
reverse the anticoagulant effects of heparin derivatives and
warfarin [8–12]. Currently there is no consensus on how to
reverse the anticoagulant effects of novel oral anticoagulants
such as apixaban, dabigatran, and rivaroxaban. Thus, options
to manage the accidental ingestion or overdose of these
agents are desirable. Given that novel oral anticoagulants are
direct reversible inhibitors, their anticoagulant effect could
be reduced by limiting systemic exposure through decreased
absorption, enhanced elimination, or both.
Activated charcoal adsorbs drugs present in the gastro-
intestinal (GI) tract, reducing the amount of drug available
for absorption into the systemic circulation [13–15]. It may
also enhance elimination by interrupting reabsorption of
drugs that are excreted directly into the intestinal tract from
the systemic circulation (enteroenteric recycling) or in bile
(enterohepatic recycling) [16–21]. In human volunteer
studies, administration of activated charcoal for up to 4 h
after overdose limited exposure to many different chemicals
to varying degrees, and was effective in treating overdose
with a wide variety of drugs [22, 23], including digoxin,
phenytoin, carbamazepine, and acetaminophen [24, 25].
However, no consistent relationship between the chemical
characteristics of a drug and the maximum adsorptive
capacity of activated charcoal has been identified [26].
Apixaban is formulated as an immediate-release tablet.
Apixaban is rapidly absorbed following oral administra-
tion, reaching peak plasma concentration (Cmax) typically
within 3 h of administration. Oral bioavailability is
approximately 50 %, and pharmacokinetics (PK) are linear
over the therapeutic dose range. Absorption of oral apix-
aban appears to be mainly within the small intestine [27].
Food and changes in gastric pH have no clinically relevant
effect on apixaban exposure [28, 29]. Elimination occurs
through multiple pathways, including metabolism and renal
and biliary excretion, with a terminal half-life (T) of
approximately 12 h [30, 31]. Intravenous studies in bile-
duct cannulated (BDC) beagle dogs and rats have indicated
that direct intestinal excretion may also be involved in the
elimination of apixaban [31–33], and further studies in
dogs have demonstrated that activated charcoal reduces
apixaban bioavailability and may also facilitate elimination
by interrupting enteroenteric recycling [33]. The present
study was designed to assess the effect of activated char-
coal on apixaban PK in healthy human subjects.
2 Methods
2.1 Study Design and Treatments
This was a single-center, open-label, randomized, three-
treatment, three-period crossover study conducted in healthy
human subjects. Treatments administered were as follows:
(A) apixaban 20 mg (four 5-mg tablets as a single dose);
(B) apixaban 20 mg, with activated charcoal 50 g adminis-
tered at 2 h post-dose; and (C) apixaban 20 mg, with activated
charcoal 50 g administered at 6 h post-dose. For all treat-
ments, apixaban was administered after a minimum 10-h fast.
The 20-mg dose of apixaban used in this study represents
the high end of the dose range evaluated in clinical trials and
is several-fold higher than the currently approved dosages
for thromboprophylaxis following knee and hip replacement
surgery (2.5 mg twice daily) and for the prevention of stroke
and systemic embolism in patients with atrial fibrillation
(5 mg twice daily). The 50-g dose of activated charcoal
selected for this study is the standard for treating overdose in
adults [34]. Charcoal was administered as Actidose (Pad-
dock Laboratories, Inc., Minneapolis, MN, USA), an aque-
ous suspension of 50 g of activated charcoal and 96 g of
sorbitol in 240 mL of water. Administration of activated
charcoal at 2 h after apixaban dosing was selected to dem-
onstrate the effect of charcoal soon after apixaban ingestion;
2 h is similar to the time frame that often elapses before
treating an overdose in the emergency room. The 6-h post-
dose time point was also chosen for administration of acti-
vated charcoal to assess whether activated charcoal is
effective at a time when the majority of apixaban absorption
has already occurred.
Subjects were randomly assigned to one of six treatment
sequences with a washout period of at least 4 days between
treatments. Randomization was carried out according to a
computer-generated scheme. Subjects were required to
remain at the clinical facility for the duration of the study.
The study protocol was approved by IntegReview Eth-
ical Review Board (Austin, TX, USA) and conducted in
compliance with all local regulations, the Declaration of
Helsinki, and the International Conference on Harmonisa-
tion Guidelines for Good Clinical Practice.
2.2 Study Population
The study recruited healthy male and female subjects
(defined as normal with respect to medical history, physical
examination, 12-lead electrocardiogram [ECG], and
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clinical laboratory determinations) who were 18–45 years
of age and had a body mass index of 18–32 kg/m2. Sub-
jects provided written informed consent prior to study
commencement.
Key exclusion criteria included any significant chronic
or acute medical illness, any history or evidence of
abnormal bleeding or coagulation disorder, intracranial
hemorrhage, any abnormal bleeding or coagulation disor-
der in a first-degree relative, any history of GI-related
disorders that would impact absorption of apixaban or
otherwise influence apixaban PK, and any contraindication
to the use of activated charcoal. Subjects were also
excluded if they smoked more than ten cigarettes per day,
were unable or unwilling to comply with the dietary
requirements of the study, or were unable or unwilling to
use adequate contraception throughout the study. In addi-
tion, female subjects were excluded if they were pregnant
or breastfeeding.
2.3 Pharmacokinetic Sampling and Analysis
Blood samples for PK analysis were collected using veni-
puncture or an indwelling catheter immediately before
dosing with apixaban and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 6.5,
8, 10, 12, 18, 24, 36, 48, and 72 h post-dose. Blood samples
at 2 or 6 h post-dose were taken immediately prior to
administration of activated charcoal, where applicable.
Apixaban plasma concentration was determined using a
validated liquid chromatography/atmospheric pressure
ionization tandem mass spectrometry method by Intertek
Pharmaceutical Services (formally known as Alta Analyt-
ical Laboratory, El Dorado Hills, CA, USA), with a lower
limit of quantification of 1 ng/mL. The between-run and
within-run variability, expressed as coefficient of variation,
for apixaban in quality-control samples was B5.58 and
B7.54 %, respectively, with deviations from the nominal
concentration of no more than ±7.14 %. Stability of
apixaban in human plasma was established for at least
864 days at -20 C, and all samples were analyzed within
this period of analyte stability. For calculation of PK
parameters, plasma concentrations with values below the
lower limit of quantification before the first measurable
concentration were treated as zero, and treated as missing
at all other times.
Subjects were excluded from the PK analysis if they
experienced emesis within 6 h of apixaban dosing (all
regimens) or within 30 min of activated charcoal admin-
istration (regimens B and C). Apixaban PK parameters
were derived from plasma concentration versus time data
with non-compartmental methods using Phoenix Win-
Nonlin, version 6.1 (Pharsight, St. Louis, MO, USA). The
Cmax and time to reach Cmax (Tmax) were obtained from
experimental observations. The terminal-phase rate
constant (k) was calculated using linear regression of the
log-linear plasma concentration–time curve. The T was
estimated as ln2/k. The area under the concentration–time
curve from time 0 to the last measurable plasma concen-
tration (AUC(0–T)) was calculated using the linear-up, log-
down trapezoidal rule. The AUC from time 0 to infinity
(AUCINF) was calculated by summing AUC(0–T) and the
extrapolated area, determined by dividing the last predicted
concentration by k [35].
2.4 Safety Assessments
Safety assessments included adverse events, clinical labo-
ratory tests, vital sign measurements, physical examina-
tions, and 12-lead ECGs. Adverse events were collected
from spontaneous reports—elicited through open-ended
questioning, examination, or evaluation of the subject—
and reviewed for clinical significance and relation to study
drug use. All adverse events were coded by system organ
class, severity, and preferred term, according to the Med-
ical Dictionary for Regulatory Activities (MedDRA, ver-
sion 14.0). Blood and urine samples for clinical laboratory
tests, including hematology, serum chemistry, and urinal-
ysis, were collected at screening on the day before study
commencement and on the second day of each treatment
period, as well as at discharge or early termination from the
study. Vital signs were assessed at screening, at study
commencement, before administration of each apixaban
dose, and at study termination. Twelve-lead ECGs were
recorded at screening, study commencement, and study
discharge. Any marked abnormalities in clinical test results
or vital signs were assessed for clinical significance by the
investigator.
2.5 Statistical Methods
The sample size was not determined based on statistical
power considerations. Assuming log-normal distributions
of AUCINF and Cmax, and intra-subject standard deviations
of 0.20 for apixaban log(Cmax) and 0.19 for apixaban
log(AUC) (data on file, protocol CV185033, Bristol-Myers
Squibb Company), data from 12 subjects were expected to
provide 90 % confidence that the geometric mean ratio of
apixaban, with and without activated charcoal, was within
14 and 13 % of the true values for Cmax and AUC,
respectively.
A general linear mixed-effect model analysis was per-
formed on ln(Cmax), ln(AUC(0–T)), and ln(AUCINF) using
treatment, period, and sequence as fixed effects and mea-
surements within subjects as repeated measures. Point
estimates and 90 % confidence intervals (CIs) for the dif-
ferences on the log scale were exponentiated to obtain
estimates for the ratios of geometric means and for 90 %
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CIs on the original scale. Apixaban alone was the reference
treatment. PK parameters were summarized using
descriptive statistics; geometric means and coefficients of
variation were presented for Cmax, AUC(0–T), and AUCINF;
medians, minima, and maxima were reported for Tmax; and
means and standard deviations were reported for T. All
statistical analyses were carried out using SAS, version 9.1
or higher (SAS Institute, Cary, NC, USA).
3 Results
3.1 Subject Disposition
The clinical phase of the study took place from 6–17 May
2011; 18 subjects were enrolled, all of whom completed the
study. Demographics and baseline characteristics of the
study population are shown in Table 1. All subjects were
included in the summary of safety data. Five subjects were
excluded from the PK analysis because of emesis that
occurred after administration of the activated charcoal sus-
pension (four receiving activated charcoal at 2 h after apixaban,
and one receiving activated charcoal at 6 h after apixaban).
3.2 Pharmacokinetics
The mean plasma concentration–time profiles for apixaban
are shown in Fig. 1; PK parameters are summarized in
Table 2. Following a single oral 20-mg dose, mean plasma
concentrations of apixaban were quantifiable for up to 72 h
without activated charcoal, but only for up to 48 h with
activated charcoal administered at 2 and 6 h post-dose
(Fig. 1). Activated charcoal had no effect on the Cmax or Tmax
of apixaban, whereas the AUC and T were reduced.
Apixaban exposure decreased by 50 and 28 %, respectively,
when activated charcoal was administered post-dose at 2 h
(ratio of adjusted geometric mean for AUCINF 0.496; 90 %
CI 0.450–0.547) and 6 h (ratio of adjusted geometric mean
for AUCINF 0.723; 90 % CI 0.661–0.792). The mean T for
apixaban (13.4 h) decreased to 5.3 and 4.9 h, respectively,
with 2- and 6-h post-dose administration of activated charcoal.
3.3 Safety
A total of 15 subjects reported 102 adverse events during
the study, all of which resolved by study completion. Most
reported adverse events were considered mild (38.9 %) or
moderate (44.4 %) in severity. There were no withdrawals
from the study because of adverse events.
Overall, a higher proportion of subjects reported adverse
events following 2- and 6-h post-dose administration of acti-
vated charcoal (72.2 and 77.8 %, respectively) compared with
apixaban alone (16.7 %). Adverse events reported by at least
two subjects (11.1 %) included diarrhea, nausea, abdominal
pain or discomfort, vomiting, abdominal distension, eructa-
tion, flatulence, asthenia, and oropharyngeal pain. All other
adverse events were reported by one subject each, including
an instance of mild gingival bleeding that occurred following a
2-h post-dose administration of activated charcoal and
resolved without treatment. GI disorders, which occurred
primarily with the activated charcoal-containing regimens,
were consistent with the known tolerability profile of activated
charcoal [34]; seven of the eight emeses occurred within 2 h
following administration of activated charcoal.
There were no clinically significant laboratory abnor-
malities and no apparent treatment-related trends observed
in clinical laboratory results, vital sign measurements,
physical examination findings, or 12-lead ECG results.
4 Discussion
The Cmax of apixaban typically occurs approximately 3 h
following administration. Therefore, activated charcoal was
expected to decrease the bioavailability of apixaban when
administered 2 h after the apixaban dose. Administration of
activated charcoal at 6 h post-dose was not expected to have
a significant impact, since apixaban was expected to be
largely through its initial absorptive phase by that time.
The results of this study confirm that activated charcoal
administered 2 h after apixaban decreases apixaban expo-
sure, as evidenced by a 50 % decrease in the apixaban
Table 1 Demographic and baseline characteristics
Characteristic Overall (n = 18)
Age (years)







Black or African American 4 (22.2)
Height (cm)
Mean (SD) 169.4 (14.6)
Range 147.3–198.5
Weight (kg)
Mean (SD) 72.2 (18.6)
Range 51.4–111.1
BMI (kg/m2)
Mean (SD) 24.7 (2.7)
Range 20.8–29.2
BMI body mass index, SD standard deviation
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AUCINF. Based on these findings, activated charcoal may
be useful in the management of apixaban overdose or
accidental ingestion. The 28 % decrease in apixaban
exposure observed following administration of activated
charcoal at 6 h post-dose suggests that the effect of acti-
vated charcoal may be due to more than a decrease in
apixaban bioavailability. Furthermore, the decrease in the
T of apixaban from *13 to *5 h when activated char-
coal was given at 2 or 6 h post-dose indicates that activated
charcoal increases the elimination of apixaban in the GI
tract. These data suggest that apixaban may undergo some
degree of recycling between the systemic circulation and
the GI tract, and that the presence of activated charcoal in
the GI tract interrupted this recycling, resulting in
enhanced elimination of apixaban via the feces. The
apparent increased elimination of apixaban in the presence
of charcoal could be potentially useful in situations other
than overdose involving higher than desirable exposure of
apixaban.
Enterohepatic recycling of apixaban does not appear to
be a likely pathway since biliary excretion of apixaban in
humans is limited. Biliary aspirate has been collected from
healthy subjects administered a single oral 20-mg dose of
radiolabeled apixaban [30]. In that study, bile collection
began 3 h after apixaban administration, continued for 5 h,
and concluded with the administration of cholecystokinin
to ensure complete emptying of the gallbladder. Biliary
excretion of unchanged apixaban accounted for less than
3 % of the total recovered radioactivity, with less than half
of that attributed to unchanged apixaban. Thus, adsorption
of this limited amount of apixaban to activated charcoal
would not result in the 28 % decrease in apixaban AUC or
the shorter T observed following administration of char-
coal 6 h after apixaban.
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Fig. 1 Mean (standard
deviation) plasma
concentration–time profiles for
apixaban alone and with
activated charcoal given at 2
and 6 h post-dose, using linear
(upper panel) and semi-
logarithmic (lower panel) scales
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Alternatively, apixaban may undergo enteroenteric
recycling (i.e., reabsorption of drug excreted from the
systemic circulation directly into the intestine). Animal
studies provide support for the involvement of enteroen-
teric recycling in the disposition of apixaban [31, 33].
Apixaban was recovered from the feces of BDC rats and
dogs administered intravenous [14C]apixaban. Approxi-
mately 20–30 % and 40–50 % of the dose, respectively,
was found in the feces of BDC rats and dogs. Adminis-
tration of activated charcoal to BDC dogs increased fecal
recovery and apparent systemic clearance, suggesting that
activated charcoal prevents reabsorption of apixaban by
interrupting enteroenteric recycling [33]. A similar study in
BDC rats administered intravenous apixaban showed a
36 % increase in fecal recovery following oral adminis-
tration of activated charcoal [33]. While apixaban is not a
substrate of the major uptake transporters, apixaban is a
P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP) substrate [36]. Further investigation in rats sug-
gested that the intestinal efflux transporters P-gp and BCRP
may be involved in the intestinal excretion of apixaban.
When intravenous apixaban was administered to BDC rats
in the presence of GF-120918, an inhibitor of P-gp and
BCRP, fecal recovery was reduced by 34 % [33].
Activated charcoal reduces systemic exposure to a wide
variety of orally administered drugs in humans by
adsorbing the drug in the GI tract and preventing absorp-
tion. However, for some drugs that are excreted into the GI
tract, either via bile or across the GI mucosa, elimination is
also enhanced, resulting in a shorter half-life in the pre-
sence of charcoal [16–19, 37, 38]. Presumably this occurs
because adsorption of the drug to charcoal creates an
increased concentration gradient for excretion into the
lumen of the GI tract and/or because reabsorption is pre-
vented, either or both of which can increase the rate of
elimination from the body [18, 19]. Thus, the decreased
half-life of apixaban in the presence of activated charcoal
in this study is consistent with increased elimination into
the GI tract and/or decreased reabsorption, resulting in an
increased rate of elimination from the body. It should be
noted that an activated charcoal product containing sorbi-
tol, Actidose, was used in this study to improve the pal-
atability of the activated charcoal preparation in this
healthy volunteer population. Activated charcoal-contain-
ing sorbitol products are not recommended because of the
increased risk of emesis and aspiration [39].
Absorption throughout the GI tract, resulting in a pro-
longed absorption phase, is another possible explanation
for the findings of this study; however, apixaban appears to
be most readily absorbed in the upper small intestine, based
on the results of a study evaluating the potential for
regional differences in the absorption of apixaban [27]. In
that three-way crossover study, a single dose of apixaban
2.5 mg as solution was administered orally or delivered to
either the distal small bowel or the ascending colon via an
EnterionTM capsule. Compared with oral administration,
the Cmax and AUC(0–T) for apixaban were approximately
60 % lower when the drug was released in the distal small







Apixaban 20 mg ?
activated charcoal
2 h after apixaban
(n = 14)a
C
Apixaban 20 mg ?
activated charcoal





AUC(0–T) (ngh/mL) 4,080 (27) 2,007 (30) 2,954 (32) B vs A: 0.503 (0.456–0.554)
C vs A: 0.737 (0.674–0.806)
AUCINF (ngh/mL) 4,185 (26) 2,034 (30) 2,976 (32) B vs A: 0.496 (0.450–0.547)
C vs A: 0.723 (0.661–0.792)
Cmax (ng/mL) 380 (30) 366 (34) 383 (30) B vs A: 0.999 (0.903–1.105)
C vs A: 1.030 (0.939–1.130)
Tmax (h) 2.5 (1.0–4.0) 2.5 (1.5–2.5) 2.5 (1.5–4.0)
T (h) 13.4 (5.1) 5.3 (1.1) 4.9 (1.2)
Geometric mean (% coefficient of variation) for AUC(0–T), AUCINF, and Cmax. Median (range) for Tmax. Mean (SD) for T
AUC(0–T) area under the plasma concentration–time curve from time zero to last observed concentration, AUCINF area under the plasma
concentration–time curve from time zero to infinity, Cmax peak plasma concentration, CI confidence interval, SD standard deviation, T apparent
terminal half-life, Tmax time to Cmax
a Four subjects were excluded from the analysis of treatment B and one from the analysis of treatment C because of emesis
b Results were estimated using the general linear mixed-effect model
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bowel; Cmax and AUC(0–T) were 90 and 84 % lower,
respectively, when apixaban was released in the ascending
colon [27]. These results indicate that the relative bio-
availability of apixaban is significantly decreased in the
distal GI tract; therefore, adsorption of apixaban to acti-
vated charcoal in the distal GI tract would not be expected
to have a significant effect on apixaban exposure [27].
The objective of this study was to assess the effect of
activated charcoal on apixaban exposure. It was not designed
to identify the specific mechanisms by which activated
charcoal affects apixaban disposition. Therefore, evaluation
of these data through compartmental analyses or other
modelling approaches, such as that described by Friberg
et al. [40] and Isbister et al. [41], may provide a more com-
plete understanding of charcoal’s effect on apixaban bio-
availability versus clearance. The role of enteroenteric
recirculation in apixaban disposition could be further char-
acterized through additional clinical study; for example, an
assessment of intestinal recovery following intravenous
administration of radiolabeled apixaban. While the effect of
activated charcoal on apixaban exposure is evident from the
results of this study, its effectiveness in patients following an
apixaban overdose or in other situations that warrant
reduction of apixaban exposure remains to be determined.
Additional factors encountered in the clinical setting, such as
the size of the overdose or the length of time that has elapsed
before the patient receives activated charcoal, may be
influential when considering potential treatment strategies.
In summary, apixaban was well tolerated in the healthy
subjects in this study, with the majority of reported adverse
events being consistent with the known adverse event
profile of activated charcoal [42]. Administration of acti-
vated charcoal up to 6 h after apixaban ingestion resulted
in a decrease in apixaban exposure. Activated charcoal
appears to both reduce the bioavailability and interrupt the
enteroenteric recycling of apixaban, leading to a more
rapid elimination of apixaban. The results of this study
suggest that activated charcoal administration may be
useful in the clinical management of apixaban overdose or
other clinical situations that warrant a reduction in apix-
aban exposure.
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